What Is The Predicted Revenue Outlook For The Acquired Autoimmune Hemolytic Anemia Market To Surpass $2.81 Billion?
Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Big Is The Acquired Autoimmune Hemolytic Anemia Market Today And What Is Its Future Size?
In recent times, there has been a substantial growth in the market size of acquired autoimmune hemolytic anemia. Its market size is expected to escalate from $2.01 billion in 2024 to about $2.14 billion in 2025, with a compound annual growth rate (CAGR) of roughly 6.5%. The notable growth during the historical period is due to factors like enhanced diagnosis rates, a surge in the occurrence of secondary AIHA, development of hospital hematology units, support from the government and regulatory bodies, and increased fund allocation towards hematology.
Expectations are high for a robust expansion in the market size for acquired autoimmune hemolytic anemia in the coming years. By 2029, it’s predicted to reach $2.81 billion with a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this projected growth include a rise in autoimmune diseases, a better comprehension of the complement system’s function, increased collaborations between biopharma and academic establishments, a surge in personalized medicine usage, and an aging population. Foreseen trends for this period encompass the incorporation of targeted biologic therapies, progress in complement pathway inhibitors, the application of AI and data analysis in illness management, AI-assisted clinical trial formations, and enhancements in orphan drug development.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp
Which Factors Are Steering Growth In The Acquired Autoimmune Hemolytic Anemia Market?
The escalating incidence of autoimmune diseases is projected to drive the advancement of the acquired autoimmune hemolytic anemia market in the future. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy cells and tissues, viewing them as harmful invaders. The surge in autoimmune diseases is primarily due to increased environmental triggers and lifestyle changes that interfere with immune system control. This rise in autoimmune diseases results in an increased rate of acquired autoimmune hemolytic anemia, as people with autoimmune diseases are more likely to develop secondary AIHA due to immune system malfunctions. For example, the autoimmune registry, an organization based in the US that collects and assesses data on autoimmune diseases, reported in 2022 that the percentage of patients diagnosed with multiple autoimmune conditions increased from 52% in 2021 to 55% in 2022. Consequently, the growing incidence of autoimmune diseases is expected to propel the acquired autoimmune hemolytic anemia market.
How Is The Acquired Autoimmune Hemolytic Anemia Market Organized By Different Segments?
The acquired autoimmune hemolytic anemia market covered in this report is segmented –
1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test
2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Specialty Clinics, Research Institutions
Subsegments:
1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count
2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count
3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test
4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing
What Current And Upcoming Trends Are Shaping The Acquired Autoimmune Hemolytic Anemia Market?
Major corporations active in the autoimmune hemolytic anemia market are prioritizing developments in targeted treatments, such as humanized monoclonal antibodies, with the goals of enhancing the success of therapies, reducing adverse effects, and offering more customized care possibilities to patients suffering from autoimmune hemolytic anemia. Humanized monoclonal antibodies are laboratory-crafted proteins engineered to simulate human antibodies. They are primarily composed of human structures, but they incorporate a small fraction of non-human, typically mouse, antibodies to augment their antigen targeting ability while reducing the risk of rejection by the immune system. For example, in February 2022, the French healthcare firm Sanofi gained the approval of the U.S. Food and Drug Administration (FDA), a US governmental agency, for Enjaymo (sutimlimab-jome), the first and only treatment for cold agglutinin disease (CAD), a scarce form of autoimmune hemolytic anemia. Enjaymo acts by selectively blocking C1s in the classical complement pathway, thereby preventing the immune system from erroneously attacking and eliminating healthy red blood cells, and thus reducing the necessity for red blood cell transfusions among CAD patients. More specifically, Enjaymo targets C1-activated hemolysis without interfering with the lectin or alternative complement pathways.
Who Are The Primary Market Leaders In The Acquired Autoimmune Hemolytic Anemia Market?
Major companies operating in the acquired autoimmune hemolytic anemia market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Rakshit Drugs Private Limited, Aarti Pharmalabs Ltd.
Access The Complete Report Here:
How Do Regional Dynamics Influence The Acquired Autoimmune Hemolytic Anemia Market Performance?
North America was the largest region in the acquired autoimmune hemolytic anemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=24132&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
